Click on the API name to know their properties
|Composit uses/ indication of Pantoflux-DSR :|
Acute nausea and vomiting, Dyspepsia, Functional dyspepsia, Gastric distension pain due to pressure on the stomach, Gastro-oesophageal reflux disease, Nausea and vomiting, Nausea and vomiting (chemotherapy induced), Nausea and vomiting (L-dopa induced), Non-ulcer dyspepsia, Reflux oesophagitis.
Duodenal ulcer. Gastric ulcer. Reflux oesophagitis, Prophylaxis of NSAID associated peptic ulcer, Zollinger-ellison syndrome and other hypersecretory states.
|Composit contra indication of Pantoflux-DSR :|
Allergy, Serious resistant GI mycoses, Hepatic impairment.
Hypersensitivity and lactation.
|Composit side effects of Pantoflux-DSR :|
Anaphylactic shock, angioedema, allergic reaction, increased prolactin levels, agitation, nervousness, extrapyramidal side effects, convulsions, somnolence, headache, gastro-intestinal disorders, transient intestinal Cramps, hives, itch, rash, galactorrhoea, excessive development of the breasts in males, amenorrhoea, ventricular arrhythmias, QTc prolongation, liver function test abnormal.
Weakness, Dizziness, Nausea, Vomiting, Anxiety, Dyspnea, Pain, Pharyngitis, Cough, Arthralgia, Rhinitis, Chest pain, Bronchitis, Backache, Urinary frequency, UTI, Hyperlipidemia, Migraine, Neck pain, Rectal disorders, Hypertonia, Sinusitis, Flu like syndrome, Hyperglycemia.
|Composit caution of Pantoflux-DSR :|
Phaeochromocytoma, children below 2 yr, elderly, renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment, monitor liver function regularly (if enzymes increase, discontinue), not recommended in children <18 yr, long term use may lead to atrophic gastritis.
Glaxo Smithkline Pharmaceuticals Ltd.